ReviewDrug design, development and therapy2026
Compound Chamomile and Lidocaine Hydrochloride Gel in Oral Diseases: A Review of Current Evidence and Potential Applications.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral diseases frequently entail microbial infections or mucosal damage, typically accompanied by pain and discomfort. Present pharmaceutical interventions for oral conditions in clinical settings are constrained by their singular therapeutic effects, insufficient pain relief, and practical inconveniences. The exploration of novel compound medications holds promise for augmenting clinical treatment outcomes. Compound chamomile and lidocaine hydrochloride gel (CCLHG) represents a composite formulation endowed with analgesic, anti-inflammatory, and wound healing properties, showcasing auspicious potential in oral disease management. This article summarizes the articles of CCLHG in treating various oral diseases. Electronic databases PubMed, Embase, Web of Science, Cochrane Library, Wangfang, China National Knowledge Infrastructure and China Science and Technology Journal Database were searched from inception to August 30, 2025. A total of 1413 articles were searched. 27 articles were finally included. Our analysis reveals preliminary therapeutic potential of CCLHG in managing periodontal diseases, oral mucosal conditions, pericoronitis, dry socket syndrome, peri-implantitis, and related maladies. However, given the overall limited sample sizes, variability in methodology, and generally moderate-to-low quality of the included studies, these findings warrant caution. Further high-quality investigations are therefore essential to substantiate its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.